A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.

نویسندگان

  • Yuan C Ding
  • Lesley McGuffog
  • Sue Healey
  • Eitan Friedman
  • Yael Laitman
  • Shani- Paluch-Shimon
  • Bella Kaufman
  • Annelie Liljegren
  • Annika Lindblom
  • Håkan Olsson
  • Ulf Kristoffersson
  • Marie Stenmark-Askmalm
  • Beatrice Melin
  • Susan M Domchek
  • Katherine L Nathanson
  • Timothy R Rebbeck
  • Anna Jakubowska
  • Jan Lubinski
  • Katarzyna Jaworska
  • Katarzyna Durda
  • Jacek Gronwald
  • Tomasz Huzarski
  • Cezary Cybulski
  • Tomasz Byrski
  • Ana Osorio
  • Teresa Ramóny Cajal
  • Alexandra V Stavropoulou
  • Javier Benítez
  • Ute Hamann
  • Matti Rookus
  • Cora M Aalfs
  • Judith L de Lange
  • Hanne E J Meijers-Heijboer
  • Jan C Oosterwijk
  • Christi J van Asperen
  • Encarna B Gómez García
  • Nicoline Hoogerbrugge
  • Agnes Jager
  • Rob B van der Luijt
  • Douglas F Easton
  • Susan Peock
  • Debra Frost
  • Steve D Ellis
  • Radka Platte
  • Elena Fineberg
  • D Gareth Evans
  • Fiona Lalloo
  • Louise Izatt
  • Ros Eeles
  • Julian Adlard
  • Rosemarie Davidson
  • Diana Eccles
  • Trevor Cole
  • Jackie Cook
  • Carole Brewer
  • Marc Tischkowitz
  • Andrew K Godwin
  • Harsh Pathak
  • Dominique Stoppa-Lyonnet
  • Olga M Sinilnikova
  • Sylvie Mazoyer
  • Laure Barjhoux
  • Mélanie Léoné
  • Marion Gauthier-Villars
  • Virginie Caux-Moncoutier
  • Antoine de Pauw
  • Agnès Hardouin
  • Pascaline Berthet
  • Hélène Dreyfus
  • Sandra Fert Ferrer
  • Marie-Agnès Collonge-Rame
  • Johanna Sokolowska
  • Saundra Buys
  • Mary Daly
  • Alex Miron
  • Mary Beth Terry
  • Wendy Chung
  • Esther M John
  • Melissa Southey
  • David Goldgar
  • Christian F Singer
  • Muy-Kheng Maria Tea
  • Daphne Gschwantler-Kaulich
  • Anneliese Fink-Retter
  • Thomas V O Hansen
  • Bent Ejlertsen
  • Oskar T Johannsson
  • Kenneth Offit
  • Kara Sarrel
  • Mia M Gaudet
  • Joseph Vijai
  • Mark Robson
  • Marion R Piedmonte
  • Lesley Andrews
  • David Cohn
  • Leslie R DeMars
  • Paul DiSilvestro
  • Gustavo Rodriguez
  • Amanda Ewart Toland
  • Marco Montagna
  • Simona Agata
  • Evgeny Imyanitov
  • Claudine Isaacs
  • Ramunas Janavicius
  • Conxi Lazaro
  • Ignacio Blanco
  • Susan J Ramus
  • Lara Sucheston
  • Beth Y Karlan
  • Jenny Gross
  • Patricia A Ganz
  • Mary S Beattie
  • Rita K Schmutzler
  • Barbara Wappenschmidt
  • Alfons Meindl
  • Norbert Arnold
  • Dieter Niederacher
  • Sabine Preisler-Adams
  • Dorotehea Gadzicki
  • Raymonda Varon-Mateeva
  • Helmut Deissler
  • Andrea Gehrig
  • Christian Sutter
  • Karin Kast
  • Heli Nevanlinna
  • Kristiina Aittomäki
  • Jacques Simard
  • Amanda B Spurdle
  • Jonathan Beesley
  • Xiaoqing Chen
  • Gail E Tomlinson
  • Jeffrey Weitzel
  • Judy E Garber
  • Olufunmilayo I Olopade
  • Wendy S Rubinstein
  • Nadine Tung
  • Joanne L Blum
  • Steven A Narod
  • Sean Brummel
  • Daniel L Gillen
  • Noralane Lindor
  • Zachary Fredericksen
  • Vernon S Pankratz
  • Fergus J Couch
  • Paolo Radice
  • Paolo Peterlongo
  • Mark H Greene
  • Jennifer T Loud
  • Phuong L Mai
  • Irene L Andrulis
  • Gord Glendon
  • Hilmi Ozcelik
  • Anne-Marie Gerdes
  • Mads Thomassen
  • Uffe Birk Jensen
  • Anne-Bine Skytte
  • Maria A Caligo
  • Andrew Lee
  • Georgia Chenevix-Trench
  • Antonis C Antoniou
  • Susan L Neuhausen
چکیده

BACKGROUND We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers. METHODS IRS1 rs1801123, rs1330645, and rs1801278 were genotyped in samples from 36 centers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analyzed by a retrospective cohort approach modeling the associations with breast and ovarian cancer risks simultaneously. Analyses were stratified by BRCA1 and BRCA2 status and mutation class in BRCA1 carriers. RESULTS Rs1801278 (Gly972Arg) was associated with ovarian cancer risk for both BRCA1 (HR, 1.43; 95% confidence interval (CI), 1.06-1.92; P = 0.019) and BRCA2 mutation carriers (HR, 2.21; 95% CI, 1.39-3.52, P = 0.0008). For BRCA1 mutation carriers, the breast cancer risk was higher in carriers with class II mutations than class I mutations (class II HR, 1.86; 95% CI, 1.28-2.70; class I HR, 0.86; 95%CI, 0.69-1.09; P(difference), 0.0006). Rs13306465 was associated with ovarian cancer risk in BRCA1 class II mutation carriers (HR, 2.42; P = 0.03). CONCLUSION The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers and breast cancer risk in BRCA1 class II mutation carriers. IMPACT These findings may prove useful for risk prediction for breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

BRCA in breast cancer: ESMO clinical recommendations.

Familial susceptibility to breast cancer accounts for 25% of all breast cancer cases. In familial breast cancer, mutations in the BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account for 5–10% of breast and ovarian cancer cases overall. The prevalence of BRCA1 or BRCA2 mutations varies considerably between ethnic groups and geographical areas. Populationspecific mutations have been described in Ice...

متن کامل

Breast Cancer Incidence After Risk-Reducing Salpingo- Oophorectomy in BRCA1 and BRCA2 Mutation Carriers

Premenopausal risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers effectively reduces ovarian cancer risk, but also reduces breast cancer risk. Breast cancer risk reductions up to 50%have been reported for both BRCA1 and BRCA2mutation carriers, but recent prospective studies were not able to reproduce this finding for BRCA1 mutation carriers. Breast cancer incidence after RR...

متن کامل

A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.

BRCA1 and BRCA2 carriers are at increased risk for both breast and ovarian cancer, but estimates of lifetime risk vary widely, suggesting their penetrance is modified by other genetic and/or environmental factors. The BRCA1 and BRCA2 proteins function in DNA repair in conjunction with RAD51. A preliminary report suggested that a single nucleotide polymorphism in the 5' untranslated region of RA...

متن کامل

Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers

Women carrying BRCA1 and BRCA2 mutations have significantly elevated risk of developing breast and ovarian cancers. BRCA1-associated breast cancer likely originates from progenitors of the luminal epithelial lineage. Recent studies indicate that radiation therapy (RT) for BRCA1 cancer patients is associated with lower incidence of developing subsequent ipsilateral breast cancer. In the current ...

متن کامل

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

BACKGROUND Risk-reducing salpingo-oophorectomy (RRSO) is widely used by carriers of BRCA1 or BRCA2 (BRCA1/2) mutations to reduce their risks of breast and ovarian cancer. To guide women and their clinicians in optimizing cancer prevention strategies, we summarized the magnitude of the risk reductions in women with BRCA1/2 mutations who have undergone RRSO compared with those who have not. MET...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

دوره 21 8  شماره 

صفحات  -

تاریخ انتشار 2012